Opportunities and Challenges in Precision Neurotherapeutics

Precision neurotherapeutics represents a transformative paradigm shift from standardized “one-size-fits-all” treatments of neurological, neurodegenerative, and/or psychiatric disorders toward individualized interventions that leverage patient-specific biological, behavioral, and physiological characteristics. Traditional neurotherapeutic approaches achieve modest response rates of 30–60% for first-line treatments, necessitating personalized strategies that account for individual differences in genetics, brain structure and function, and treatment response profiles. This review examines advances across three core domains: pharmaceutical approaches utilizing fragment-based drug discovery, pharmacokinetic modeling, and quantitative systems pharmacology; neuromodulation technologies evolving from open-loop to adaptive closed-loop systems with real-time biomarker feedback; and biomarker development spanning neuroimaging, pharmacogenomics, and digital health applications. Critical challenges include developing robust methodological frameworks for single-subject parameter estimation, addressing signal-to-noise ratio limitations in neuroimaging, and navigating complex regulatory landscapes. The convergence of artificial intelligence, computational modeling, and US Food and Drug Administration policy shifts toward in silico approaches creates unprecedented opportunities for mechanistically informed biomarkers that can guide truly personalized mental health care.